エドガーで原本を確認する
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of June 2023
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. |
|
Description |
|
|
|
Exhibit 99.1 |
|
Announcement relating to blocklisting six monthly return |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
HUTCHMED (CHINA) LIMITED |
|
|
|
|
|
|
|
|
By: |
/s/ Johnny Cheng |
|
Name: |
Johnny Cheng |
|
Title: |
Chief Financial Officer |
Date: June 29, 2023
3
Exhibit 99.1
Blocklisting Six Monthly Return
Hong Kong, Shanghai, & Florham Park, NJ — Thursday, June 29, 2023: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM; HKEX: 13) announces the following blocklisting six monthly return:
1. |
Name of applicant: |
|
HUTCHMED (China) Limited |
|
2. |
Name of scheme: |
|
(a) |
Share Option Scheme conditionally adopted by HUTCHMED in 2005 (“2005 HUTCHMED Share Option Scheme”) |
|
|
(b) |
Share Option Scheme conditionally adopted by HUTCHMED in 2015 (“2015 HUTCHMED Share Option Scheme”) |
|
3. |
Period of return: |
|
From December 29, 2022 to June 28, 2023 |
|
4. |
Balance under scheme from previous return: |
|
(a) |
2005 HUTCHMED Share Option Scheme: 883,300 ordinary shares of US$0.1 each |
|
(b) |
2015 HUTCHMED Share Option Scheme: 52,667,578 ordinary shares of US$0.1 each |
||
5. |
The amount by which the block scheme has been increased, if the scheme has been increased since the date of the last return: |
|
(a) |
2005 HUTCHMED Share Option Scheme: Nil |
|
|
(b) |
2015 HUTCHMED Share Option Scheme: Nil |
|
6. |
Number of securities issued/allotted under scheme during period: |
|
(a) |
2005 HUTCHMED Share Option Scheme: 449,250 |
|
|
(b) |
2015 HUTCHMED Share Option Scheme: 936,860 |
|
7. |
Balance under scheme not yet issued/allotted at end of the period: |
|
(a) |
2005 HUTCHMED Share Option Scheme: 434,050 ordinary shares of US$0.1 each |
|
|
(b) |
2015 HUTCHMED Share Option Scheme: 51,730,718 ordinary shares of US$0.1 each |
|
8. |
Number and class of securities originally listed and the date of admission: |
|
25,198,880 ordinary shares of US$0.1 each admitted on June 17, 2019 (to replace the Company’s previous block admission schemes following the Company’s share subdivision which took effect on May 30, 2019) |
|
|
|
|||
|
|
|||
|
|
|||
9. |
Total number of securities in issue at the end of the period: |
|
866,161,450 ordinary shares of US$0.1 each |
|
|
Name of contact: |
|
Weiguo Su |
||
|
Address of contact: |
|
Level 18, The Metropolis Tower, 10 Metropolis Drive, Hung Hom, Kowloon, Hong Kong |
||
Telephone number of contact: |
|
+852 2121 8200 |
||
About HUTCHMED
HUTCHMED (Nasdaq/AIM: HCM; HKEX: 13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has approximately 5,000 personnel across all its companies, at the center of which is a team of about 1,800 in oncology/immunology. Since inception it has focused on bringing cancer drug candidates from in-house discovery to patients around the world, with its first three oncology drugs now approved and marketed in China. For more information, please visit: www.hutch med.com or follow us on LinkedIn.
CONTACTS
Investor Enquiries |
|
Mark Lee, Senior Vice President |
+852 2121 8200 |
Annie Cheng, Vice President |
+1 (973) 567 3786 |
|
|
Media Enquiries |
|
Americas – Brad Miles, Solebury Strategic Communications |
+1 (917) 570 7340 (Mobile) | bmiles@soleburystrat.com |
Europe – Ben Atwell / Alex Shaw, FTI Consulting |
+44 20 3727 1030 / +44 7771 913 902 (Mobile) / +44 7779 545 055 (Mobile) | HUTCHMED@fticonsulting.com |
Asia – Zhou Yi, Brunswick |
+852 9783 6894 (Mobile) | HUTCHMED@brunswickgroup.com |
|
|
Nominated Advisor |
|
Atholl Tweedie / Freddy Crossley / Daphne Zhang, |
+44 (20) 7886 2500 |